Haemato AG (HAEK) - Net Assets
Based on the latest financial reports, Haemato AG (HAEK) has net assets worth €- EUR (≈ $- USD) as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€- ≈ $- USD) and total liabilities (€- ≈ $- USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Haemato AG (HAEK) cash conversion ratio to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | 1.69% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Haemato AG - Net Assets Trend (2021–2022)
This chart illustrates how Haemato AG's net assets have evolved over time, based on quarterly financial data. Also explore Haemato AG (HAEK) total assets for the complete picture of this company's asset base.
Annual Net Assets for Haemato AG (2021–2022)
The table below shows the annual net assets of Haemato AG from 2021 to 2022. For live valuation and market cap data, see HAEK market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | €147.17 Million ≈ $172.06 Million |
+1.69% |
| 2021-12-31 | €144.73 Million ≈ $169.20 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Haemato AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 9.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €29.46 Million | 20.02% |
| Other Components | €117.71 Million | 79.98% |
| Total Equity | €147.17 Million | 100.00% |
Haemato AG Competitors by Market Cap
The table below lists competitors of Haemato AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Delta Technologies Nyrt
BUD:DELTA
|
$64.93 Million |
|
Everspring Industry Co Ltd
TW:2390
|
$64.93 Million |
|
Kamux Suomi Oy
HE:KAMUX
|
$64.95 Million |
|
Catalyst Bancorp Inc
NASDAQ:CLST
|
$64.99 Million |
|
SMCore.Inc
KQ:007820
|
$64.90 Million |
|
DMS Propertindo Tbk PT
JK:KOTA
|
$64.89 Million |
|
NEW ZEALAND RURAL
F:8UK
|
$64.89 Million |
|
Mercor S.A.
WAR:MCR
|
$64.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Haemato AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 144,725,954 to 147,168,177, a change of 2,442,223 (1.7%).
- Net income of 8,192,570 contributed positively to equity growth.
- Dividend payments of 5,750,347 reduced retained earnings.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €8.19 Million | +5.57% |
| Dividends Paid | €5.75 Million | -3.91% |
| Total Change | €- | 1.69% |
Book Value vs Market Value Analysis
This analysis compares Haemato AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.46x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €27.68 | €13.00 | x |
| 2022-12-31 | €28.14 | €13.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Haemato AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.57%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.30%
- • Asset Turnover: 1.41x
- • Equity Multiplier: 1.20x
- Recent ROE (5.57%) is above the historical average (5.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 4.51% | 2.29% | 1.57x | 1.26x | €-7.94 Million |
| 2022 | 5.57% | 3.30% | 1.41x | 1.20x | €-6.52 Million |
Industry Comparison
This section compares Haemato AG's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,058,012,174
- Average return on equity (ROE) among peers: -98.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Haemato AG (HAEK) | €- | 4.51% | N/A | $64.92 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $54.11 Billion | 6.89% | 0.98x | $1.19 Billion |
| PEPTONIC MEDICAL (28L) | $75.32 Million | -56.54% | 0.42x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.95 Billion | 11.12% | 0.39x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $201.51 Million | -13.72% | 0.07x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.51 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $29.16 Million | -49.27% | 0.13x | $13.93 Million |
| EQL PHARMA AB (7JK) | $221.03 Million | 19.51% | 2.66x | $80.44 Million |
About Haemato AG
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements. In addition, it provides pharmaceuticals in the areas of HI… Read more